PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

With the widespread use of PD‐1/PD‐L1 monoclonal antibodies (mAbs) in the treatment of multiple malignant tumors, they were also gradually applied to advanced renal cell carcinoma (aRCC). Nowadays, multiple PD‐1/PD‐L1 mAbs, such as nivolumab, avelumab, and pembrolizumab, have achieved considerable e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Lei, Dong, Hui yu, Zhou, Tian ren, Wang, Yu hao, Yan, Tao, Li, Jun chen, Wang, Zhong yuan, Li, Jie, Liang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446416/
https://www.ncbi.nlm.nih.gov/pubmed/34382349
http://dx.doi.org/10.1002/cam4.4190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446416/
https://www.ncbi.nlm.nih.gov/pubmed/34382349
http://dx.doi.org/10.1002/cam4.4190

Ejemplares similares